These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Listed as ongoing, but also has a completion date||2019-001876-12||A multicentre, uncontrolled trial on the contraceptive efficacy, safety, tolerability and pharmacokinetics of LPRI-424 (dienogest 2 mg / ethinyl estradiol 0.02 mg) during 13 cycles||2022-05-26||bad-data|
|Listed as ongoing, but also has a completion date||2019-001877-97||A multicentre, double-blind, double-dummy, randomised trial on the contraceptive efficacy, tolerability and safety of LPRI-424 (dienogest 2 mg / ethinyl estradiol 0.02 mg) during nine cycles in compar...||2022-03-22||bad-data|
|Ongoing||2019-002350-22||Multi-center, phase 2, open-label, randomized clinical trial to evaluate the inhibition of ovulation of 3 dosing strengths of levonorgestrel (LNG) vaginal delivery system (VDS), releasing during 28 da...||not-yet-due|
|No trial status on register||2020-000412-30||A multicenter, open-label, controlled study to investigate the effect of LF111 on bone mineral density (BMD) in adolescent and adult women in comparison with non-users of hormonal contraceptive method...||bad-data|
|Reported results Terminated||2020-005015-40||A multicentre, phase III, double-blind, randomised, parallel, placebo-controlled trial to assess efficacy and safety of early administration of Ivermectin during 3 consecutive days to prevent SARS CoV...||2021-06-21||due-trials|
|Other||2021-001424-17||A multicentre, phase III, double-blind, randomised clinical trial to assess the efficacy and safety of LPRI-CF113 in the treatment of endometriosis versus placebo after 3 medication cycles followed by...||not-yet-due|
|Other||2021-002178-17||A multicentre, phase III, double-blind, randomised clinical trial to assess the efficacy and safety of LPRI-424 (dienogest 2.00 mg / ethinyl estradiol 0.02 mg) in the treatment of polycystic ovary syn...||not-yet-due|